122 related articles for article (PubMed ID: 7663590)
21. Advantages for the use of the activated clotting time (ACT).
Pesola DA; Pesola HR; Pesola GR
Am J Crit Care; 1995 Sep; 4(5):414-5. PubMed ID: 7489050
[No Abstract] [Full Text] [Related]
22. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
[TBL] [Abstract][Full Text] [Related]
23. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
24. Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.
Bowers J; Ferguson JJ
Tex Heart Inst J; 1993; 20(4):258-63. PubMed ID: 8298321
[TBL] [Abstract][Full Text] [Related]
25. Defining the optimal activated clotting times during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
Helft G; Beygui F; le Feuvre C; Metzger JP
Circulation; 2001 Nov; 104(22):E124. PubMed ID: 11723037
[No Abstract] [Full Text] [Related]
26. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
[TBL] [Abstract][Full Text] [Related]
27. The use of activated clotting times to monitor heparin therapy during and after interventional procedures.
Bowers J; Ferguson JJ
Clin Cardiol; 1994 Jul; 17(7):357-61. PubMed ID: 8088021
[TBL] [Abstract][Full Text] [Related]
28. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
29. Validation of a bedside activated clotting time test (Hemochron Jr II Signature) with low dose heparin therapy.
Racioppi L; Quinart A; Biais M; Nouette-Gaulain K; Revel P; Sztark F
Anaesthesia; 2009 Apr; 64(4):430-4. PubMed ID: 19317710
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention.
Díez JG; Cheong BY; O'Meallie LP; Alt EU
J Interv Cardiol; 2004 Oct; 17(5):307-13. PubMed ID: 15491334
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
[TBL] [Abstract][Full Text] [Related]
32. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats.
Greene CE; Meriwether E
Am J Vet Res; 1982 Aug; 43(8):1473-7. PubMed ID: 7103231
[TBL] [Abstract][Full Text] [Related]
33. Implications for cardiac surgery in patients with factor XII deficiency.
Conaglen PJ; Akowuah E; Theodore S; Atkinson V
Ann Thorac Surg; 2010 Feb; 89(2):625-6. PubMed ID: 20103363
[TBL] [Abstract][Full Text] [Related]
34. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
[TBL] [Abstract][Full Text] [Related]
35. Commentary on: The relationship between heparin level and activated clotting time in the adult cardiac surgery population.
Fitzgerald D
Perfusion; 2009 Mar; 24(2):97. PubMed ID: 19654151
[No Abstract] [Full Text] [Related]
36. Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery.
Patteril M; Stafford-Smith M; Toffaletti JG; Bute BP; Milano CA; Welsby IJ
Clin Chim Acta; 2005 Jun; 356(1-2):218-24. PubMed ID: 15936321
[TBL] [Abstract][Full Text] [Related]
37. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research.
Wilkerson RD; Conran PB; Greene SL
Lab Anim Sci; 1984 Feb; 34(1):62-5. PubMed ID: 6716959
[TBL] [Abstract][Full Text] [Related]
38. Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty.
Helft G; Choktron S; Beygui F; Le Feuvre C; Elalamy I; Metzger JP; Vacheron A; Samama MM
Cathet Cardiovasc Diagn; 1998 Nov; 45(3):329-31. PubMed ID: 9829899
[TBL] [Abstract][Full Text] [Related]
39. Management of prekallikrein deficiency during cardiac surgery.
Eeckhoudt SL; Momeni M; Matta A; Latinne D; Arnout J; Hermans C
Thromb Haemost; 2010 Apr; 103(4):866-7. PubMed ID: 20135073
[No Abstract] [Full Text] [Related]
40. [Heparin management by activated coagulation time during cardiopulmonary bypass].
Shikano K; Shinpo H; Nasu M; Morimoto T; Suzuki T; Yada I; Kusagawa M
Kyobu Geka; 1981; 34(12):934-7. PubMed ID: 7349352
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
